115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Asciminib (ASC) in combination with Imatinib (IMA), nilotinib (NIL), or dasatinib (DAS) may be a potential treatment (Tx) option in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase (Ph + CML-CP/AP): Final results from the asciminib phase 1 study
    Meeting Abstract

    Cortes, J.; Lang, F.; Rea, D.; Hochhaus, A.; Breccia, M.; Goh, Y. T.; Heinrich, M. C.; Hughes, T. P.; Janssen, J. J. W. M.; le Coutre, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A simple prediction model of outcomes after allogeneic hematopoietic stem cell transplant (HCT) in myelodysplastic syndromes using HCT-comorbidity index, cytogenetic risk, and platelet count
    Meeting Abstract

    Frumm, S. M.; Kim, H. T.; Kelkar, A. H.; Ho, V. T.; Gooptu, M.; Gibson, C. J.; Koreth, J.; Shapiro, R. M.; Romee, R.; Nikiforow, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with clinical high-risk newly diagnosed multiple myeloma (NDMM) with an inadequate response to frontline autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2c extended follow-up
    Meeting Abstract

    Dhodapkar, M. V.; Alsina, M.; Berdeja, J. G.; Patel, K. K.; Richard, S.; Vij, R.; Leleu, X.; Egan, D. N.; Bergsagel, P. L.; Reshef, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) in children and young adults with low-risk classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo): Early results from the phase 2 KEYNOTE-667 study
    Meeting Abstract

    Roth, L. G.; Keller, F.; Toledo, M. M.; Castellino, S. M.; Forlenza, C. J.; Catalan, M. A.; Krystal, J.; Lamble, A.; Rao, A. V.; Morales, F. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • (131)I-apamistamab-led allogeneic hematopoietic cell transplant significantly improves overall survival in patients with TP53 mutated R/R AML
    Meeting Abstract

    Choe, H.; Tomlinson, B. K.; Gyurkocza, B.; Nath, R.; Seropian, S.; Litzow, M. R.; Abboud, C. N.; Stiff, P. J.; Abhyankar, S.; Foran, J. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Post-transplant cyclophosphamide eliminates disparity in GvHD-free, relapse-free survival and overall survival between 8/8 matched and 7/8 mismatched unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies
    Meeting Abstract

    Auletta, J. J.; Al Malki, M. M.; DeFor, T.; Shaffer, B. C.; Gooptu, M.; Bolanos-Meade, J.; Abboud, R.; Briggs, A. D.; Khimani, F.; Modi, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comparable survival of treatment naive TP53 mutated acute myeloid leukemia treated with hypomethylating agent compared to hypomethylating agent plus venetoclax based therapy
    Meeting Abstract

    Badar, T.; Atallah, E. L.; Shallis, R. M.; Patel, A. A.; Correia, G. S. D. C.; Goldberg, A. D.; Saliba, A.; Bewersdorf, J. P.; Duvall, A. S.; Bradshaw, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk acute myeloid leukemia (AML) and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) maintenance post-hematopoietic cell transplant (HCT)
    Meeting Abstract

    DiPersio, J.; Cooper, B. W.; Suh, H. C.; Koura, D.; Bernard, L.; Shah, N. N.; Walter, R. B.; Perales, M. A.; Mapara, M.; Tamari, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical implications of TP53 mutations/allelic state in patients (Pts) with myelodysplastic syndromes/neoplasms (MDS) treated with hypomethylating agents (HMA)- a multicenter, retrospective analysis from the VALIDATE database
    Meeting Abstract

    Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Intensive induction chemotherapy (IC) vs hypomethylating agents plus venetoclax (HMA/VEN) in IDH1-or IDH2-mutant newly diagnosed acute myeloid leukemia (AML) - A multicenter cohort study
    Meeting Abstract

    Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; Lindsley, R. C.; more...
    Blood (2023)

    Fulltext@MSK | Save